SCHEMBL6206623

SCHEMBL6206623

CNCCNc1nnc(-c2ccc(F)c(F)c2Nc2ccc(CCO)cc2F)o1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.36
CAMK2B Q13554 1/20 0.36
MAP2K1 Q02750 9/20 0.33
MAP2K2 P36507 3/20 0.33
KDR P35968 4/20 0.33
FLT1 P17948 2/20 0.33
RXFP1 Q9HBX9 1/20 0.32
PDCD1 Q15116 3/20 0.32
CD274 Q9NZQ7 3/20 0.32
CYP3A4 P08684 1/20 0.31
TUBB4A P04350 2/20 0.31
TUBB P07437 2/20 0.31
TUBA3C P0DPH7 2/20 0.31
TUBA1B P68363 2/20 0.31
TUBA4A P68366 2/20 0.31
TUBB4B P68371 2/20 0.31
TUBB3 Q13509 2/20 0.31
TUBB2A Q13885 2/20 0.31
TUBB8 Q3ZCM7 2/20 0.31
TUBA3E Q6PEY2 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6399433 0.92 MAP2K1 (0.37) MAP2K1MAP2K2KDRRXFP1PDCD1
SCHEMBL6398977 0.90 KDR (0.34) PIM1CAMK2BMAP2K1MAP2K2KDR
SCHEMBL6205699 0.86 MAP2K1 (0.37) MAP2K1MAP2K2KDRFLT1RXFP1
SCHEMBL6398520 0.85 PIM1 (0.46) PIM1CAMK2BMAP2K1MAP2K2
SCHEMBL6190172 0.84 CHRNA7 (0.44) MAP2K1MAP2K2CYP3A4
SCHEMBL6207302 0.80 PDCD1 (0.39) MAP2K1MAP2K2KDRRXFP1PDCD1
SCHEMBL6208327 0.80 MAP2K1 (0.52) PIM1CAMK2BMAP2K1MAP2K2
SCHEMBL6207841 0.79 MAP2K1 (0.36) MAP2K1MAP2K2KDRFLT1RXFP1
SCHEMBL6207184 0.79 FLT1 (0.39) KDRFLT1
SCHEMBL6190835 0.79 CHRNA7 (0.45) CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578736-A1 MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES Warner-Lambert Company LLC (US) 2005-09-28 EP claimed
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US claimed
WO-2004056789-A1 MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES WARNER-LAMBERT COMPANY LLC (US) 2004-07-08 WO claimed
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004186-A1 MEK inhibiting compounds MAPK1, MAP3K1, MAPK3 PIM1 74/4885CAMK2B 1041/4885MAP2K1 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.